About us

The middle east gene and cell therapy company was founded in Iran in 2018 and became a knowledge-based company in 2019.
This company established a branch in the United Arab Emirates called SAM Gene and Cell Therapy, which formed the MEGCT brand by merging the two companies.
The company currently represents the American Board of Regenerative Medicine (ABRM) and is active in advanced technologies in the field of cell therapy and gene therapy.
MEGCT has been able to offer more than 10 effective medical indications and treatment protocols.
These indications include skin and hair diseases, orthopedic diseases, pain and rehabilitation, neuropathy, cancer, autoimmune diseases, metabolic diseases, urology, women, infertility, cardiovascular, brain and nerves
The products of the Middle East gene and cell therapy company with brands ” Max Cell, Sif Cell, Exoserum, Nika Cell, and CIK Cell” are currently undergoing clinical trials.
Exoserum is the most commonly used product of the company, which is the secretion of mesenchymal stem cells containing unique and multiple growth factors and anti-inflammatory factors that can be used with mesenchymal stem cells or alone. By activating tissue stem cells, Exoserum accelerates its healing process. This product is produced and sold under the license of the company RBC, Regenerative Bio Cell.
All the process of research, development, and production of these products have been localized with experienced experts of this company.
More than 200 Iranian professions are members of the customer club of this company, collaborating with the Middle East gene and cell therapy company to improve related treatment protocols in the field of regenerative medicine.
More than 30 experts in various countries under the ABRM group also collaborate with SAM Gene and Cell Therapy in the United Arab Emirates.